이상반응 보고

VAERS ID	2247518
성별	남성
나이	45세
주 코드	FR
제약회사	MODERNA
로트 번호
예방접종 횟수	3
접종일	2022-03-30
발병일	2022-03-30
상태	입원

증상

• 근육통(Myalgia)

이환 중 질병

지병

기타 의료

이전 예방접종

알레르기

임상 검사

증상 상세

Muscle pain; This regulatory authority case was reported by an other health care professional and describes the occurrence of MYALGIA (Muscle pain) in a 45-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.
No Medical History information was reported.
On 30-Mar-2022, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form.
On 30-Mar-2022, the patient experienced MYALGIA (Muscle pain) (seriousness criterion hospitalization).
At the time of the report, MYALGIA (Muscle pain) was resolving.
For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.
Concomitant product use was not provided by the reporter.
On 30-Mar-2022 patient received third Moderna vaccine and then began to have fever and chest tightness.
On 01-Apr-2022, came to ER for consultation and treatments.
Vital signs included T/P/R: 37.
1/111/22; BP: 124/84 mmHg; SpO2: 96%; Troponin I: < 0.
01; CRP: 0.
59; ECG: Sinus tachycardia CCWR.
.
Treatment medications included N/S 500 ml 1 bottle ST, Keto 1 vial ST, and Lactam 500 mg 1 tab ST were administered and the patient was hospitalized.
On 04-Apr-2022, ECG: NSR CCWR; Troponin I: < 0.
01; CPK: 54.
On 05-Apr-2022, drugs taken at discharge included Lactam 500 mg 1 tab TID, and Kinzolam 2 mg 1tab.
Company comment: This regulatory authority case concerns a 45-year-old male patient with no medical history reported, who experienced the unexpected serious event of Myalgia (seriousness criterion Hospitalization) which occurred same day after the third dose of mRNA-1273 vaccine.
Patient was treated with N/S 500 ml 1 bottle ST, Keto 1 vial ST, and Lactam 500 mg 1 tab ST and Vital signs were T/P/R: 37.
1/111/22; BP: 124/84 mmHg; SpO2: 96%; Troponin I: < 0.
01; CRP: 0.
59; ECG: Sinus tachycardia as on 1-Apr-2022 and discharged with medication Lactam and Kinzolam.
The benefit-risk relationship of mRNA-1273 is not affected by this report.
Event's seriousness retained as per Regulatory Authority reporting.
; Sender's Comments: This regulatory authority case concerns a 45-year-old male patient with no medical history reported, who experienced the unexpected serious event of Myalgia (seriousness criterion Hospitalization) which occurred same day after the third dose of mRNA-1273 vaccine.
Patient was treated with N/S 500 ml 1 bottle ST, Keto 1 vial ST, and Lactam 500 mg 1 tab ST and Vital signs were T/P/R: 37.
1/111/22; BP: 124/84 mmHg; SpO2: 96%; Troponin I: < 0.
01; CRP: 0.
59; ECG: Sinus tachycardia as on 1-Apr-2022 and discharged with medication Lactam and Kinzolam.
The benefit-risk relationship of mRNA-1273 is not affected by this report.
Event's seriousness retained as per Regulatory Authority reporting.